


FORM PTO-1390 (REV. 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO. 100564-00111	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				DATE: May 10, 2002	
				U.S. APPLN. NO. (IF KNOWN, SEE 37 C.F.R. 1.5) 10/089,521	
INTERNATIONAL APPLICATION NO. PCT/EP00/09588		INTERNATIONAL FILING DATE September 29, 2000		PRIORITY DATE CLAIMED September 29, 1999	
TITLE OF INVENTION: USE OF GANGLIOSIDES AND OTHER SUBSTANCES FOR MODULATING SPHINGOLIPID-CHOLESTEROL MICRODOMAINS					
APPLICANT(S) FOR DO/EO/US: Mikael SIMONS, Tim FRIEDRICHSON, Kai SIMONS and Teymuras KURZCHALIA					
<p>1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. (THE BASIC FILING FEE IS ATTACHED)</p> <p>2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures [35 U.S.C. 371(f)] at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper demand for International Preliminary Amendment was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed [35 U.S.C. 371(c)(2)]</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English [35 U.S.C. 371(c)(2)].</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].</p> <p>Items 11 - 16 below concern other document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: Request for Refund, PCT/ISA/210 and PCT/ISA/220</p>					

U.S. APPLICATION (IF KNOWN) SEE 37 C.F.R. 1.50) 10/089,521		INTERNATIONAL APPLICATION NO. PCT/EP00/09588		ATTORNEY DOCKET NO. 100564-00111			
				DATE: May 10, 2002			
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee [37 C.F.R. 1.492(a)(1)-(5)]: Search Report has been prepared by the EPO or JPO.....\$890.00 International preliminary examination fee paid to USPTO (37 C.F.R. 1.482).....\$710.00 No international preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but international search fee paid to USPTO (37 C.F.R. 1.445(a)(2)).....\$740.00 Neither international preliminary examination fee (37 C.F.R. 1.482) or international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO.....\$1,040.00 International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 100.00				CALCULATIONS		PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 0.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date [37 C.F.R. 1.492(e)].				\$ 130.00			
Claims		Number Filed		Number Extra		Rate	
Total Claims		- 20 =				X \$ 18.00 \$	
Independent Claims		- 3 =				X \$ 84.00 \$	
Multiple dependent claim(s) (if applicable)				+ \$280.00		\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 130.00			
Reduction by one-half for filing by small entity. The applicant is entitled to small entity status.				\$ 65.00			
SUBTOTAL =				\$ 65.00			
Processing fee of \$130.00 for furnishing the English translation later the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 C.F.R. 1.492(f)].				+		\$ 0.00	
TOTAL NATIONAL FEE =				\$ 0.00			
Fee for recording the enclosed assignment [37 C.F.R. 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				+		\$ 40.00	
TOTAL FEES ENCLOSED =				\$ 105.00			
5/2002 LLANDGRA 00000040 10089521				Amount to be refunded		\$	
				Charged		\$	
a. <input checked="" type="checkbox"/> A check in the amount of \$105.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 01-2300 in the amount of \$ to cover the above fee. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2300.							
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive [37 C.F.R. 1.137(a) or (b)] must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPONDENCE TO: Arent Fox Kintner Plotkin & Kahn 1050 Connecticut Avenue, N.W. Suite 400 Washington, D.C. 20036-5339 Tel: (202) 857-6000 Fax: (202) 638-4810 RBM/ars							
				 Robert B. Murray Reg. No. 22,980			

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: SIMONS et al.

**Refund Section
Accounting Division
Office of Finance**

Serial No. 10/089,521

Filed: March 29, 2002

Attorney Dkt. No.: 100564-00111

For: USE OF GANGLIOSIDES AND OTHER SUBSTANCES FOR MODULATION
SPHINGOLIPID-CHOLESTEROL MICRODOMAINS

REQUEST FOR REFUND

Commissioner for Patents
Washington, D.C. 20231

May 10, 2002


Sir:

The undersigned respectfully requests a refund of 445.00 (\$445.00) from the Large entity filing fee paid on March 29, 2002. The applicant herein is entitled to Small Entity Status under 37 CFR 1.9(f) and 1.27(b) and, therefore, it is believed that a refund in the amount of one half of the filing fee is proper.

It is respectfully requested that the refund be credited to the undersigned's Deposit Account No. 01-2300. A duplicate copy of this sheet is enclosed herewith.

Respectfully submitted,

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC


Robert B. Murray
Registration No. 22,980

Customer No. 004372
1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810
RBM/ars